Kwang‐Hyub Han

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

Hepatology, Medicine, Randomised Phase 3 +11

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

Ting‐Tsung Chang, Robert G. Gish, Robert de Man et al. · New England Journal of Medicine · 2006 · 1.4K citations · Full text

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Thomas Karlas, David Petroff, M. Sasso et al. · Journal of Hepatology · 2016 · 1.2K citations · Full text

Controlled Attenuation Parameter, Clinical Endpoint, Laboratory Medicine +3

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro et al. · The Lancet Oncology · 2015 · 1.1K citations

Surgical Oncology, Hepatology, Medicine +8

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

Yun‐Fan Liaw, Jia‐Horng Kao, Teerha Piratvisuth et al. · Hepatology International · 2012 · 1K citations

Hepatitis D, Hepatology, Viral Hepatitis +10